

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 14/41, A23G 9/02</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/37673</b> <b>(43) International Publication Date:</b> 29 July 1999 (29.07.99)
<b>(21) International Application Number:</b> PCT/EP98/08554 <b>(22) International Filing Date:</b> 23 December 1998 (23.12.98) <b>(30) Priority Data:</b> 9801420.2 22 January 1998 (22.01.98) GB <b>(71) Applicant (for all designated States except AU BB CA CY GB GD GH IE IL KE LK LS MN MW NZ SD SG SZ TT UG):</b> UNILEVER N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL). <b>(71) Applicant (for AU BB CA CY GB GD GH IE IL KE LK LS MN MW NZ SD SG SZ TT UG only):</b> UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SIDEBOTTOM, Christopher, Michael [GB/GB]; Unilever Research Colworth, Colworth House, Sharnbrook, Bedford MK44 1LQ (GB). SMALLWOOD, Margaret, Felicia [GB/GB]; University of York, Dept. of Biology, The Plant Laboratory, Heslington York YO1 5YW (GB). BYASS, Louise, Jane [GB/GB]; University of York, Dept. of Biology, The Plant Laboratory, Heslington York YO1 5YW (GB).		<b>(74) Agent:</b> KIRSCH, Susan, Edith; Unilever N.V., Patent Dept., P.O. Box 137, NL-3130 AC Vlaardingen (NL). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> FROZEN FOOD PRODUCT <b>(57) Abstract</b> <p>Anti-freeze protein which can be derived from Lichen, said protein having an apparent molecular weight of from 20 to 28 kDa and having an N-terminal amino acid sequence which shows at least 80 % overlap with: A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L and modified versions and isoforms of this protein.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Frozen Food product5 Technical Field of the Invention

The invention relates to anti-freeze proteins (AFPs) and frozen food product containing AFPs.

10 Background to the Invention

Anti-freeze proteins (AFPs) have been suggested for improving the freezing tolerance of foodstuffs.

15 For the purpose of the invention, the term AFP has the meaning as well-known in the art, namely those proteins which exhibit the activity of inhibit the growth of ice crystals. See for example US 5,118,792.

20 WO 90/13571 discloses antifreeze peptides produced chemically or by recombinant DNA techniques. The AFPs can suitably be used in food-products.

WO 92/22581 discloses AFPs from plants which can be used  
25 for controlling ice crystal shape in ice-cream. This document also describes a process for extracting a polypeptide composition from extracellular spaces of plants by infiltrating leaves with an extraction medium without rupturing the plants.

WO 94/03617 discloses the production of AFPs from yeast and their possible use in ice-cream. WO 96/11586 describes fish AFPs produced by microbes.

5 Several literature places also mention the isolation and/or use of plant proteins for cryoprotection. Cryoprotective proteins have a function in the protection of plant membranes against frost damage. These proteins, however, do not possess recrystallisation inhibition properties and  
10 are, therefore, not embraced within the terms AFPs.

Hincha in Journal of Plant Physiology, 1992, 140, 236-240 describes the isolation of cryoprotective proteins from cabbage. Volger in Biochimica et Biophysica Acta, 412  
15 (1975), 335-349 describes the isolation of cryoprotective leaf proteins from spinach. Boothe in Plant Physiol (1995), 108: 759-803 describes the isolation of proteins from Brassica napus. Again, these proteins are believed to be cryoprotective proteins rather than AFPs. Neven in Plant  
20 Molecular Biology 21: 291-305, 1993 describes the DNA characterisation of a spinach cryoprotective protein. Salzman in Abstracts and Reviews of the 18th Annual Meeting of the ASEV/Eastern Section in Am. J. Enol. Vitic., Vol. 44, No. 4, 1993 describes the presence of boiling-stable  
25 polypeptides in buds of Vitis. Although the proteins are analogous to fish antifreeze peptides, they are cryoprotective proteins and not AFPs. Lin in Biochemical and Biophysical Research Communication, Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant Physiology (1992)  
30 99, 519-525 describes the 15 kDa cryoprotective polypeptide from Arabidopsis Hakaira. Houde in The Plant Journal (1995) 8(4), 583-593 mentions cryoprotective proteins from wheat.

Up till now, however the use of AFPs has not been applied to commercially available food products. One reason for this are the high costs and complicated process for  
5 obtaining AFPs. Another reason is that the AFPs which until now have been suggested for use in frozen food products cannot be incorporated in the standard formulation mix, because they tend to destabilise during processing especially during the pasteurisation step. This  
10 destabilisation is believed to be caused by the denaturation of the AFPs; this is a well-known effect commonly observed for peptides and proteins.

In our non pre-published patent application: WO 98/4148  
15 it has been described that particularly good AFPs can be isolated from natural sources such as Lichen.

Applicants have now been able to determine the partial amino acid sequence of a particularly active AFP from  
20 Lichen.

Accordingly the invention relates to an AFP which can be derived from Lichen, said AFP having an apparent molecular weight of about 24 kDa and an amino acid sequence from the  
25 N-terminus of:

A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L

Also embraced in the scope of our invention are proteins having a sequence which has a high degree of similarity  
30 with the above sequence. For the purpose of the invention all RI active proteins having an amino acid sequence of at least 80% overlap with the above sequence are also embraced

in the scope of the invention. More preferred is an overlap of at least 90%, most preferred more than 95%, e.g. those amino acid sequences which differ none or only one or two amino acids with the above sequence.

5

For the purpose of the invention the degree of overlap of two (partial) amino acid sequences can be calculated as follows:

(a) the two amino acid sequences are aligned and the number  
10 of amino acids which are identical and appear in the same order are counted (X)

(b) every change, deletion or addition of an amino acid is counted as 1 point, and the total of changes, deletions and additions is calculated (Y)

15 (c) the degree of overlap can now be calculated as  $X*100\%/(X+Y)$ .

For example the (partial) amino acid sequence from the N-terminus of:

20 A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L, can be aligned with the control as follows:

A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L  
A-P-A-W -M- D-A-E-S-F-G-A-I-A-H-G-G-L

25

This leads to a total number of identical amino acids in the same order of 17. The number of changes is 1 (W into V at the fourth position); the number of additions is 2 (V at fifth position, G at 7th position), while there are no  
30 deletions. The total of changes, additions and deletions is therefore 3. This leads to a degree of overlap of  $17*100\%/(17+3)= 85\%$

The protein having (partial) amino acid sequence from the N-terminus of:

A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L is hence also embraced within the invention.

5

Also embraced within the scope of the present invention are modified versions of the above described proteins whereby said modification does not materially affect the ice recrystallisation inhibition properties, such as  
10 glycosylated versions thereof.

For the purpose of the invention the term about 24 kDa molecular weight means any molecular weight from 20 to 28 kDa as measured on SDS-PAGE using standard reference  
15 markers, more preferably the molecular weight is from 22 to 26 kDa.

The advantageous AFP of the present invention can be derived from Lichen especially from the species Umbilicaria  
20 antarctica.

Also embraced within the scope of the present invention are anti-freeze proteins which although originally derived from Lichen are produced by other methods, for example by  
25 genetic modification techniques whereby for example microorganisms or plants are genetically modified to produce the above described proteins. These proteins are also embraced within the term "can be derived from Lichen".

30 Also embraced within the scope of the present are nucleic acid sequences which are capable to encode the above described AFPs.

Vectors containing a nucleic acid sequence capable of encoding the AFP of the invention are also embraced within the scope of the invention.

5

Based on the above information it is also possible to genetically modify other natural sources such that they produce the advantageous AFP as identified here-above.

10

Applicants also have found that AFPs of the above sequence have improved ice-recrystallisation inhibition properties. A suitable test for determining the ice recrystallisation inhibition properties is described in the examples and involves the quick freezing to at least -40°C, for example -80°C followed by storage for one hour at -60°C. Preferably AFPs in accordance to the invention provide a ice particle size following an ice recrystallisation inhibition assay - as described in the examples- of 15 µm or less, more preferred from 5 to 15 µm.

The AFP of the invention can conveniently be used in food products, preferably in food products which are frozen or intended to be frozen. Especially preferred is the use of AFPs in products which are heated e.g. by pasteurisation or sterilisation prior to freezing. Especially preferred is the use in frozen confectionery products.

Examples of such food products are: frozen confectionery mixes such as ice-cream mixes and water-ice mixes which are intended to be pasteurised prior to freezing. Such mixes



are usually stored at ambient temperature. Suitable product forms are for example: a powder mix which is packed for example in a bag or in sachets. Said mix being capable of forming the basis of the frozen food product e.g. after addition of water and optionally other ingredients and optional- aeration.

Another example of a suitable mix could be a liquid mix (optionally aerated) which, if necessary after addition of further components and optional further aeration can be frozen.

The clear advantage of the above mentioned mixes is that the presence of the AFP ingredient makes that the mixes can be frozen under quiescent conditions, for example in a shop or home freezer without the formation of unacceptable ice crystal shapes and hence with a texture different to products normally obtained via quiescent freezing.

Very conveniently these mixes are packed in closed containers (e.g. cartons, bags, boxes, plastic containers etc). For single portions the pack size will generally be from 10 to 1000 g. For multiple portions pack sizes of up to 500 kg may be suitable. Generally the pack size will be from 10 g to 5000 g.

As indicated above the preferred products wherein the AFPs are used are frozen confectionery product such as ice-cream or water-ice. Preferably the level of AFPs is from 0.00001 to 0.5 wt% based on the final product. If dry-mixes or concentrates are used, the concentration may be higher in

order to ensure that the level in the final frozen product is within the above ranges.

For the purpose of the invention the term frozen

5 confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees. For some applications the use in fermented food products is less preferred.

10

Preferably a the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 4 wt%, for example more than 30 wt%, more preferred from 40 to 70wt%.

15 Frozen confectionery products according to the invention can be produced by any method suitable for the production of frozen confectionery. Especially preferably however all the ingredients of the formulation are fully mixed before pasteurisation and before the freezing process starts. The

20 freezing process may advantageously involve a hardening step, for example to a temperature of -30 Fahrenheit or lower.

**Example I**

The ice recrystallisation inhibition properties of the AFPs can be determined as follows:

- 5 A sample of an AFP containing product was adjusted to a sucrose level of 30 wt% (If the starting level of the sample was more than 30% this was done by dilution, if the starting level was lower sucrose was added to the 30% level).
- 10 A 3  $\mu$ L drop of the sample was placed on a 22 mm coverslip. A 16 mm diameter cover-slip was then placed on top and a 200 g weight was placed on the sample to ensure a uniform slide thickness. The edges of the coverslip were sealed
- 15 with clear nail varnish.

The slide was placed on a Linkham THM 600 temperature controlled microscope stage. The stage was cooled rapidly (50 °C per minute) to -40°C to produce a large population

20 of small crystals. The stage temperature was then raised rapidly (50°C per minute) to -6 °C and held at this temperature.

The ice-phase was observed at -6 °C using a Leica

25 Aristoplan microscope. Polarised light conditions in conjunction with a lambda plate were used to enhance the contrast of the ice crystals. The state of the ice phase (size of ice crystals) was recorded by 35 mm photomicrography at T=0 and T=1 hour. The ice-crystal size

30 (length) was determined by drawing around the perimeter of the crystals. The maximum length for each individual ice crystal of a batch of ice cream was imported into a

spreadsheet where analysis of the data set was carried out to find the mean, and standard deviation.

Another method to test ice recrystallisation inhibition properties is as follows:

Anti-freeze activity was measured using a modified "splat assay" (Knight et al, 1988). 2.5  $\mu$ l of the solution under investigation in 30% (w/w) sucrose was transferred onto a clean, appropriately labelled, 16 mm circular coverslip. A second coverslip was placed on top of the drop of solution and the sandwich pressed together between finger and thumb. The sandwich was dropped into a bath of hexane held at  $-80^{\circ}\text{C}$  in a box of dry ice. When all sandwiches had been prepared, sandwiches were transferred from the  $-80^{\circ}\text{C}$  hexane bath to the viewing chamber containing hexane held at  $-6^{\circ}\text{C}$  using forceps pre-cooled in the dry ice. Upon transfer to  $-6^{\circ}\text{C}$ , sandwiches could be seen to change from a transparent to an opaque appearance. Images were recorded by video camera and grabbed into an image analysis system (LUCIA, Nikon) using a 20x objective. Images of each splat were recorded at time = 0 and again after 30-60 minutes. The size of the ice-crystals in both assays was compared. If the size at 30-60 minutes is similar or only moderately increased (say less than 20% increased, more preferred less than 10% increased, most preferred less than 5 % increased) compared to the size at  $t=0$ , this is an indication of good ice-crystal recrystallisation inhibition properties.

Generally these tests can be applied to any suitable composition comprising AFP and water. Generally the level of AFP in such a test composition is not very critical and can for example be from 0.0001 to 0.5 wt%, more preferred 5 0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for example 0.01 wt%

Any suitable composition comprising AFP and water can be used to carry out the test. Generally, however, it will not 10 be necessary to obtain the AFP in purified form. For practical applications normally it would suffice to prepare a liquid extract or juice of natural material, wherein this extract or juice can then be tested.

**Example II**

9.5 g *Umbilicaria antarctica* collected during Spring 1996  
5 from the Antarctic and stored at -20 C was homogenised in  
liquid nitrogen in a mortar and pestle to a fine powder.  
This powder was transferred to a fresh mortar and pestle  
held at room temperature. Following the addition of 10 ml  
0.2 M Tris HCl containing 10 mM EDTA the powder was further  
10 ground in the mortar and pestle and the homogenate filtered  
through 2 layers of muslin. The retentate was replaced in  
the mortar and pestle and a further 10 ml buffer added and  
the retentate ground further. This material was filtered as  
above and the filtrate pooled with filtrate from the first  
15 homogenisation step. The filtrate was centrifuged at 30,000  
g for 15 minutes and the supernatant collected and frozen  
in aliquots.

0.15 g  $\text{NH}_4\text{SO}_4$  was dissolved in 1ml supernatant and the  
20 solution incubated for 30 minutes at 4 C. After  
centrifugation at 30,000 g for 10 minutes 0.3 g  $\text{NH}_4\text{SO}_4$  was  
dissolved in the supernatant from this step and the  
solution incubated at 4 C for 30 minutes. The solution was  
centrifuged at 30,000 g for 10 minutes and the supernatant  
25 discarded. The pellet was resuspended in 0.2 ml water and  
serial dilutions of this solution and the original extract  
prepared in 30 % (w/w) sucrose in water for semi-  
quantitative splat analysis. Splat activity could be  
detected (by the above method) in the original extract to a  
30 dilution of more than 200 fold and in the resuspended  
pellet to a dilution of 800 fold indicating that more than

half of the total splat activity present in the original extract had been harvested in the  $\text{NH}_4\text{SO}_4$  pellet.

200 microlitre 0.1 M TrisHCl pH 7.5 was added to the resuspended pellet and the solution concentrated in a 10 kDa cut-off microcon (Amicon) to 150 microlitre. 100 microlitre of this solution was applied to a Q-Sepharose column pre-equilibrated in 50 mM Tris HCl pH 7.5 using a SMART chromatography system (Pharmacia) at a flow rate of 100 microlitre per minute and 100 microlitre fractions collected. Following 800 microlitre was in 50 mM Tris HCl pH 7.5, a 0-0.5 M NaCl gradient was applied to the column over 1.5 ml and the eluate monitored at 280 nm. Following 50 fold dilution in 30 w/w % sucrose, fractions were tested for splat activity as in example I. Activity was found to correlate with a peak of OD 280 which eluted at approximately 0.1 M NaCl which was mainly collected in fraction 14.

40 microlitre fraction 14 was applied to a Superdex 75 gel permeation column pre-equilibrated in 50 mM Tris HCl pH 7.5 at a flow rate of 40 microlitre per minute using a SMART chromatography system (Pharmacia). The eluate was monitored at OD 280 and OD 215 and the 80 microlitre fractions were collected from 0.6 ml after sample application, 50 microlitre fractions between 1.1 and 1.6 ml and 100 microlitre fractions between 1.6 and 3 ml. 1 microlitre from each fraction was diluted 25 times in 30 w/w% sucrose and assayed for splat activity. Activity was found to correlate with a peak of OD280 and OD215 which eluted with a retention of 1.2 ml in fractions 9 and 10. The Superdex column was calibrated by determination of the retention

volume ( $V_e$ ) of standard protein molecular weight markers (Sigma) and the void volume ( $V_o$ ) determined as 0.91 ml by application of blue dextran. A standard curve of  $\log_{10} M_r$  against  $V_e/V_o$  was plotted and the apparent molecular weight of the OD 280 peak correlating with the lichen splat activity determined as 30 kDa.

32 microlitre from fractions 9 and 10 eluting from the Superdex column were pooled and concentrated to 10 microlitre in a 10 kDa cut-off microcom (Amicon) and 3.5 microlitre 4x SDS-PAGE sample buffer was added to 10 microlitre fractions 9 and 10 eluting from the Superdex column and to fractions 12-16 eluting from the Q-sepharose column. Following heating 95 C for five minutes and 15 centrifugation at 10,000 g for 3 minutes 10 microlitres of each sample was loaded into wells in a 4% stacking gel and polypeptides separated by electrophoresis through a 12% 0.75 mm thick SDS-PAGE mini-gel (Biorad). Following electrophoresis the gel was stained and fixed in Coomassie 20 Brilliant Blue and destained in methanol:acetic acid:water (1:4:5) w/w. This revealed a polypeptide of apparent  $M_r$  24 kDa in the concentrated pooled fractions 9 and 10 eluting from the Superdex column. When the gel was silver stained using the Biorad silver stain kit according to the 25 manufacturers instructions, a polypeptide with the same apparent  $M_r$  was detectable in fraction 14 eluting from the Q-Sepharose column and in fractions 9 and 10 eluting from the Superdex column.

30 Following purification of further protein using essentially the same methodology as described above, the following N-



terminal amino-acid sequence was obtained from the 24 kDa polypeptide:

A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L

5

### Example III

Crude lichen filtrate in accordance to example II was ammonium sulphate precipitated and resuspended in 0.2M  
10 Tris/HCl pH 7.5 as described above and then diluted 1/10 into one of the following buffers: 0.2M sodium citrate pH 3.0, 0.2M sodium acetate pH 4.0, 0.2M Piperazine pH 5.0, 0.2 M bisTris pH 6.0, 0.2 M triethanolamine pH 7.0, 0.2 M Tris pH 8.0, 0.2 M CHES pH 9.0, 0.2 M CAPS pH 10.0. These  
15 samples were then serially diluted 1/2 in the relevant buffer and the dilutions mixed 1:1 with 60% sucrose prior to splat analysis according to the second test as described in example I. Between pH 10 and pH 6.0 recrystallisation inhibition activity could be detected clearly down to a  
20 dilution of 1/320. Between pH 3.0 - 5.0 activity could be clearly detected to a dilution of 1/80 indicating that although the protein retains some activity at low pH, its activity is reduced by a factor of 4 at pH at or below 5.0.

### 25 Example IV

Purified lichen antifreeze in accordance to example II protein was separated by 2 dimensional electrophoresis. Gel containing 9.2M urea, 4% acrylamide (2.66ml 30% acrylamide  
30 0.8% bisacrylamide), 2% deionised Triton X 100, 1% 4-7 Bio-lyte ampholyte (Biorad), 1% 3.5-10 Bio-lyte ampholyte (Biorad), 0.1% TEMED, 0.01% ammonium persulphate was

polymerised in small glass tubes (Biorad). The tubes were rinsed in distilled water and inserted into a mini-gel system capable of accommodating them and the upper chamber filled with 20mM NaOH and the lower chamber with 10mM  $\text{H}_3\text{PO}_4$ .

5 Purified lichen sample was mixed 1:1 with first dimension sample buffer (9.2 M urea, 2.0% Triton X-100, 5% beta-mercaptoethanol, 1% 4-7 Bio-lyte ampholyte, 0.25% 3-10 Bio-lyte ampholyte) and warmed to 37°C prior to application to one of the tube gels. To a second rod, 2 dimensional marker

10 proteins (Biorad) were applied and to a third rod a mixture of 2 dimensional marker proteins and the lichen sample was applied. Following electrophoresis at 500V for 10 minutes and 750 V for 4 hours the rods were extruded from the tubes and loaded onto 3 separate 1mm thick 12% SDS-PAGE mini gels

15 (Biorad) and overlaid with SDS-PAGE sample buffer. Following electrophoresis the gels were silver stained using the Biorad kit according to the manufacturer's instructions. The separation revealed 3 spots on the gel in the lichen sample all with an apparent Mr of approximately

20 24 kDa and PI lower than 4.5.

1 dimensional isoelectric focussing of purified lichen antifreeze protein using a slab gel composed of the same components as in the first dimension gel in the 2

25 dimensional separation except Biolyte 3-5 ampholytes were used in the place of Biolyte 4-7 ampholytes revealed a band with an isoelectric point lower than 3.6 following silver staining.

**Claims**

1. Anti-freeze protein which can be derived from Lichen, said protein having an apparent molecular weight of from 20 to 28 kDa and having an N-terminal amino acid sequence which shows at least 80% overlap with:  
A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L  
and modified versions and isoforms of this protein
2. Anti-freeze protein of claim 1 having an N-terminal amino acid sequence as follows:  
A-P-A-V-V-M-G-D-A-E-S-F-G-A-I-A-H-G-G-L  
and modified versions and isoforms of this protein.
3. Anti-freeze protein of claim 1 or 2, having a molecular weight of from 22 to 26 kDa.
4. Anti-freeze protein of claim 1 or 2, showing at least 90% overlap with the partial sequences of claim 1 or 2.
5. Anti-freeze protein of claim 1 or 2, showing 100% overlap with the partial sequences of claim 1 or claim 2.
6. Anti-freeze protein of claim 1, wherein the modification involves glycosylation.
7. Nucleic acid sequence encoding the anti-freeze protein of one or more of the preceding claims.

8. Food product comprising an anti-freeze protein according to claim 1 or 2.
9. Food product according to claim 8 being a frozen confectionery product.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☒ **LINE(S) OR MARK(S) ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**